PINACIDIL

Details

Stereochemistry	RACEMIC
Molecular Formula	C13H19N5.H2O
Molecular Weight	263.3387
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

SMILES

O.CC(NC(NC1=CC=NC=C1)=NC#N)C(C)(C)C

InChI

InChIKey=AFJCNBBHEVLGCZ-UHFFFAOYSA-N

InChI=1S/C13H19N5.H2O/c1-10(13(2,3)4)17-12(16-9-14)18-11-5-7-15-8-6-11;/h5-8,10H,1-4H3,(H2,15,16,17,18);1H2

HIDE SMILES / InChI

Molecular Formula	C13H19N5
Molecular Weight	245.3235
Charge	0
Count	MOL RATIO 1 MOL RATIO (average)

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	1
Optical Activity	( + / - )

Molecular Formula	H2O
Molecular Weight	18.0153
Charge	0
Count	MOL RATIO 1 MOL RATIO (average)

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description

Pinacidil is a clinically effective vasodilator used for the treatment of hypertension.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Sulfonylurea receptor 2, Kir6.2 11	Opener 34		2.0 µM [EC50]
Transient receptor potential cation channel subfamily A member 1 38	Agonist 2,678		260.0 µM [EC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Hypertension 567	Primary		Approved 8,429	PINDAC

C_max

Value	Dose	Co-administered	Analyte	Population
69.7 ng/mL	12.5 mg 2 times / day multiple, oral		PINACIDIL plasma	Homo sapiens

AUC

Value	Dose	Co-administered	Analyte	Population
365.4 ng × h/mL	12.5 mg 2 times / day multiple, oral		PINACIDIL plasma	Homo sapiens

T_1/2

Value	Dose	Co-administered	Analyte	Population
10.7 h	12.5 mg 2 times / day multiple, oral		PINACIDIL plasma	Homo sapiens

Doses

Show entries

Dose	Population	Adverse events
75 mg 2 times / day multiple, oral Highest studied dose	unhealthy, 53.1 years n = 31	Other AEs: Headache, Edema...
25 mg 2 times / day multiple, oral	unhealthy, 53.6 ± 11.0 years	Disc. AE: Edema, Tachycardia...
37.5 mg 2 times / day multiple, oral	unhealthy, 53.6 ± 11.0 years	Disc. AE: Edema...

Showing 1 to 3 of 3 entries

Previous1Next

AEs

Show entries

AE	Significance	Dose	Population
Tachycardia	12.9%	75 mg 2 times / day multiple, oral Highest studied dose	unhealthy, 53.1 years n = 31
Edema	29%	75 mg 2 times / day multiple, oral Highest studied dose	unhealthy, 53.1 years n = 31
Asthenia	3.2%	75 mg 2 times / day multiple, oral Highest studied dose	unhealthy, 53.1 years n = 31
Palpitation	3.2%	75 mg 2 times / day multiple, oral Highest studied dose	unhealthy, 53.1 years n = 31
Dizziness	9.7%	75 mg 2 times / day multiple, oral Highest studied dose	unhealthy, 53.1 years n = 31

Showing 1 to 5 of 9 entries

Previous1 2Next

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1,737	substrate 1,037	substrate 1,217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
	CYP1A2 1,054 CYP2A6 543 CYP2B6 664 CYP2C8 693 CYP2C19 991 CYP2E1 667

Drug as victim

Show entries

Target	Modality	Activity
CYP3A4 1,737	substrate 3,367	major
CYP1A2 1,054	substrate 3,367	no
CYP2A6 543	substrate 3,367	no
CYP2B6 664	substrate 3,367	no
CYP2C19 991	substrate 3,367	no

Showing 1 to 5 of 9 entries

Previous1 2Next

Sourcing

Sourcing

Show entries

Vendor/Aggregator	ID	URL
001 Chemical	DY562883	https://www.001chemical.com/chem/60560-33-0
3B Scientific (Wuhan) Corp	3B3-062585	http://www.3bsc.com/index/pro_info.php?id=101708
AA Blocks	AA004OUW	https://www.aablocks.com/goods/Goods/detail?id=AA004OUW
AHH Chemical co.,ltd	MT-58006	http://www.ahhchemical.com/product/MT-58006.html
AK Scientific, Inc. (AKSCI)	2657AH	http://www.aksci.com/item_detail.php?cat=2657AH

Showing 1 to 5 of 26 entries

Previous1 2 3 4 5 6Next

PubMed

Show entries

Title	Date	PubMed
A family of sulfonylurea receptors determines the pharmacological properties of ATP-sensitive K+ channels.	1996 May	8630239
A novel sulfonylurea receptor forms with BIR (Kir6.2) a smooth muscle type ATP-sensitive K+ channel.	1996 Oct 4	8798681
Sulphonylurea receptor 2B and Kir6.1 form a sulphonylurea-sensitive but ATP-insensitive K+ channel.	1997 Mar 15	9130167

Showing 1 to 3 of 3 entries

Previous1Next

Patents

Sample Use Guides

In Vivo Use Guide

Adults: Oral: 12.5 mg twice daily, may increase at intervals of 1-2 weeks; maximum dose: 100-150 mg/day in divided doses

Route of Administration: Oral

In Vitro Use Guide

In murine WT ventricular cells, pinacidil (1-100uM) concentration-dependently induced an outward current and action potential shortening, effects that were blocked by glibenclamide, a K(ATP) channel blocker.

Substance Class	Chemical
Record UNII	7B0ZZH8P2W
Record Status	`Validated (UNII)`
Record Version

Show entries

Name

Type

Language

PINACIDIL

Official Name

English

PINDAC

Brand Name

English

GUANIDINE, N-CYANO-N'-4-PYRIDINYL-N''-(1,2,2-TRIMETHYLPROPYL)-, MONOHYDRATE

Systematic Name

English

PINACIDIL MONOHYDRATE [MI]

Common Name

English

PINACIDIL [MART.]

Common Name

English

Showing 1 to 5 of 15 entries

Previous1 2 3Next

Show entries

Classification Tree

Code System

Code

Other antihypertensives and diuretics

WHO-VATC

QC02LX01

Guanidine derivatives

WHO-ATC

C02DG01

Guanidine derivatives

WHO-VATC

QC02DG01

Other antihypertensives and diuretics

WHO-ATC

C02LX01

Agent Affecting Cardiovascular System

NCI_THESAURUS

C270

Showing 1 to 5 of 5 entries

Previous1Next

Show entries

Code System

Code

Type

Description

FDA UNII

7B0ZZH8P2W

PRIMARY

IUPHAR

2412

PRIMARY

EPA CompTox

DTXSID4045682

PRIMARY

PUBCHEM

55329

PRIMARY

CAS

85371-64-8

PRIMARY

Showing 1 to 5 of 16 entries

Previous1 2 3 4Next

Show entries

Related Record

Type

Details


					BB4UGO5K0D

PINACIDIL ANHYDROUS

PARENT -> SALT/SOLVATE


					BB4UGO5K0D

PINACIDIL ANHYDROUS

ANHYDROUS->SOLVATE

Showing 1 to 2 of 2 entries

Previous1Next

Show entries

Related Record

Type

Details


					BB4UGO5K0D

PINACIDIL ANHYDROUS

ACTIVE MOIETY

Showing 1 to 1 of 1 entries

Previous1Next

SMILES

InChI

Description<div class="info-popup-container"><div><span class="pop-sub-key ">Sources:&nbsp;</span><span class="pop-sub-val"><span class="ext-link"><a target="_self" href="https://www.ncbi.nlm.nih.gov/pubmed/2434746">https://www.ncbi.nlm.nih.gov/pubmed/2434746</a></span></span></div></div>

CNS Activity

Originator

Approval Year

Targets

Conditions

Cmax

AUC

T1/2

Doses

AEs

Overview

OverviewOther

Drug as victim

Sourcing

PubMed

Patents

Sample Use Guides

Description

C_max

T_1/2